|
JUNE 2008 — In This Issue:
|
|
|
Metabolon Offers Insight into Metabolic Age
|
|
|
Bioprocessing and Cell Line Development
|
|
|
Metabolon Awarded Additional Metabolomics Patent, Metabolon Launches mView
|
|
Metabolon Research Offers Insight into Metabolic Age
Metabolon’s chief scientific officer, Michael Milburn, along with several of Metabolon’s lead researchers recently published research on the identification of biochemical markers of aging. The research, appearing in the April edition of Pharmacogenomics, studied 269 subjects, ranging in age from 20 to 65 years old.
Conducting analysis using Metabolon’s proprietary biochemical profiling platform, blood samples from each patient revealed well over 100 biochemical markers (biomarkers) showing significant age-related changes. While some of the individual markers identified in this study have previously been identified by researchers as related to age, Metabolon’s unique global analysis provided unprecedented insight into the vast array of markers in a single analysis. By comparing the chronological age of the subjects to this global view of age-related biomarkers, the research demonstrates the ability to measure a person’s metabolic age.
Click here to read the complete publication in Pharmacogenomics.
Bioprocessing and Cell Line Development
The Challenge: Optimizing the Production of a Protein Therapeutic
It is widely understood that the production phase of bioprocessing can have a significant impact on the overall profitability of the biopharmaceutical. Organizations must analyze everything from total protein production level to glycosylation patterns as well as overall quality and stability. It is clear that the final product’s profitability can be dramatically changed by the culture process.
Protein production has been greatly improved through process monitoring of important variables such as dissolved O2, pH, lactate and carbon source depletion. Further optimization has been accomplished via formulation development using a cause and effect model as well as spent media analysis looking for a few specific rate limiting media components.
Given the large numbers of variables involved—especially in the composition of media nutrients—it is has traditionally been difficult to achieve globally optimal conditions using these methods.
Metabolon Awarded Additional Metabolomics Patent
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today that the company has been awarded another metabolomics patent. The newly issued patent further expands the domain of previously issued patents to include multiple disease states related to nervous systems disorders including Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, depression and schizophrenia.
Metabolon Launches mView
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today the availability of mView™, a data-rich biochemical profiling service for scientists in academic and government institutions.
|
Upcoming Events
|
|